We analyzed the clinicopathological features and survival rates of the patients with renal cell carcinoma younger than 50 years old.
Introduction
Renal cell carcinoma (RCC) is the most common renal parenchymalmalignancy which accounts for 3-6% of all adult malignancies and represents 85% of all renal malignant tumors [1] [2] [3] . The peak incidence of these tumors generally occurs between 60 and 70 years of age [4] . RCC is uncommon in young adults and only 3-7% of these tumors are seen under 40 years of age [2] .
Although controversial reports exist, the incidence of RCC seems to have increased during the last few decades. The incidence of RCC was reported to be 3.9% between 1975-1980 and it was detected to be 4.8% between 2000-2003 [5] . However, another recent study suggests a stable incidence rate, which was 7.5% between 1988-1994 and 7.7% between 1995-2000 [6] .
Younger patient populations are unique in that they have an increased quality of health compared to the older generations. Additionally, younger age is associated with an increased amount of anxiety due to diseases and a longer life expectancy. Hence, special consideration for counselling and management is required [7] .
In this study, we reviewed our experience with RCC in patients between the ages of 19-49 years. We report clinical and pathological characteristics, type of surgical procedures performed and survival data of these patients, and compared our results with the previous studies.
Materials and Methods
All surgical procedures were performed by single surgeon or under his supervision. Twenty-eight patients with ages ranging from 19-49 years underwent nephron-sparing surgery (NSS) or radical nephrectomy (RN) due to renal cell carcinoma (RCC) at two different centers between December 2004 and November 2007. Histopathologic frozen section analysis of tumor bed was performed to confirm the negative surgical margins of resection in all patients who underwent NSS. Patients were analyzed retrospectively with respect to presenting symptoms, histological subtypes, Fuhrman nuclear grades and pathological stage. The pathological specimen slides were re-reviewed by the same pathologist. Tumor size was calculated as the longest dimension of the lesion measured at pathologic examination. The tumors were staged according to the 2002 TNM classification and graded according to the Fuhrman grading system [8, 9] . Postoperative outcomes and follow-up were recorded by patients' chart review and patient or family interview. Descriptive statistics were used to summarize the results. Mean, standard deviation, median, minimum and maximum were presented for continuous variables; counts and percentages were presented for discrete variables. Comparisons between two groups were performed using t-test for normally distributed continuous variables. Categorical variables were analyzed using crosstab statistics. Survival data was analyzed using Kaplan Meier survival analysis. Significance level of P value was set 0.05. All statistical analysis were performed with SPSS ® version 13.0. Table 1 represents the clinical characteristics of the patients. The mean age at surgery was 41,5±7,6 years (range:19-49, median age:43). The male/female ratio was 3/1. In the present study 32,1% (n=9) of the tumors were detected incidentally, and 67,9% (n=19) of them were symptomatic. The primary symptoms in the symptomatic group were flank pain (46.4%) followed by hematuria (35.7%) and palpable flank/abdominal mass (10.7%). The classical triad (hematuria, pain and palpable mass), weight loss and fever were seen at similar frequencies (3,6% for each).
Results
Radical nephrectomy and NSS were performed in 18 (64,3%) and 10 (35,7%) patients, respectively. The mean tumor size was 6,2±4,6 cm (range: 1,5-20).
Most of the patients (n=18, 64.3%) had T1aN0M0 and T1bN0M0 disease. Only one patient had metastatic disease at presentation and received immunotherapy due to liver metastasis prior to surgery at another institution. Additionally, one patient was found to have pancreatic and mesenteric lymph node involvement at the time of RN.
Predominant histologic variant was clear cell carcinoma (19 patients, 67.9%). Other histologic types were papillary 4 (14.3%), chromophobe 3 (10.7%) and collecting duct 2 (7.1%). Eleven (39,3%), 7 (25%), 5 (17,9 %) and 5 (17,9 %) of the patients had Fuhrman grades 2, 1, 3 and 4 tumors, respectively. Table 2 represents the pathological and survival characteristics of patients according to their clinical presentation and surgical treatment.
Mean tumor diameters were 3.5±0.95 cm and 7.4±5.2 cm in the incidental and symptomatic groups, respectively, which was statistically significant (p=0.035, t test).
Patients treated with RN had larger sized tumors compared to those treated by NSS (8.0±4.9 cm versus 2.9±0.76 cm, p=0.003, t test).
Pathological staging of the tumors were significantly different between the groups treated by RN and NSS (p=0.034, Pearson Chi-square test). All of the patients who underwent NSS (n=10, 100%) had pT1 disease. However, of the patients who underwent RN, 8 (44.4%) had pT1, 2 (11.1%) had pT2, 4 (22.2%) had pT3 and 4 (22.2%) had N+ and/or M1 disease. Regarding Fuhrman grade, there was no significant difference between the groups (p=0.066, Pearson Chi-square). Of the 10 patients who underwent NSS, 5 (50%), 4 (40%) and 1 (10%) had Fuhrman grades 1, 2 and 3 tumors, respectively. On the other hand, of the 18 patients who were treated by RN, 2 (11.1%), 7 (38.9%), 4 (22.2%) and 5 (27.8%) had Fuhrman grade 1, 2, 3 and 4 tumors, respectively.
No significant differences were detected between the pathological stages when patients were classified according to their presenting symptoms (p=0.242, Pearson Chi-square). In incidentally discovered patients, 8 (88.9%) had pTl and 1(11.1%) had pT3 tumors. In the symptomatic group 10 (52.6%), 2 (10.5%), 3 (15.8%) and 4 (21.1%) patients had pT1, pT2, pT3 and N+ and/or M+ tumors, respectively. Similarly, no significant difference was detected regarding Fuhrman grades between the groups (p=0.265, Pearson Chi-square). Among symptomatic patients 4(21.1%), 6(31.6%), 4(21.1%) and 5(26.3%) had Fuhrman grade 1, 2, 3 and 4 tumors, respectively whereas among incidentally diagnosed group 3(33.3%), 5(55.6%) and 1(11.1%) patients had Fuhrman grade 1, 2 and 3 tumors, respectively.
One patient who was treated by RN in another institution was admitted to our clinic with local tumor recurrence 6 months after the primary surgery. We resected the local recurrent mass and three months after removal, a second subcutaneous recurrence developed at the incision site which we also removed. Unfortunately this patient died 18 months of follow-up. Another patient, a 24-year old pregnant woman was diagnosed with RCC during the first trimester. NSS was performed after the termination of pregnancy.
Of the 28 patients, 5 died during follow-up. Of these 5 patients, 4 died because of RCC and one patient was lost due to cerebral embolism on postoperative day 5. This patient was excluded from the survival analysis. Mean postoperative follow-up of the remaining 27 patients was 20.2 ±1.9(SE) months (range, 2-35 months).
Overall and cancer specific mortalities were 17.9% (n=5) and 14.3% (n=4), respectively. Mean survival and cancer specific survival rates were 30.6±2.1(SE) months and 85.2% (Table 1, Figure 1 ). All patients died regardless of the etiology in the symptomatic group and were all treated by RN.
Discussion
RCCs are rare in young adults and less than 10% of RCCs are seen in this age group [6] . Despite no agreement on the exact age limit in order to consider patients with RCC as young adults. Several studies accepts 35-45 years as the upper limit [2,6,10] and 14-26 as the lower limit [1] [2] [3] 7, 11] . Additionally, some of the studies even included benign lesions of the kidney in their series [5, 12] which we think affect interpretation of results. Therefore, to prevent any confusion we selected only patients with RCC in the present study.
It is known that more than 50% of RCCs are diagnosed incidentally [4] . However, this is not the case for young adults where patients with RCCs generally present when they are symptomatic [5, 11] . One possible explanation for this condition might be younger patients are generally healthier and are rarely admited for tumor screening [5] . In accordance with the literature [1, 3, [5] [6] [7] 10, 11] , 67.9% of our patients were symptomatic and prevailing symptoms were pain and hematuria. Similarly, Sanchez-Ortiz et al reported 81% incidence of symptomatic tumors in their series [11] . Higher incidence of symptomatic tumors in young patients can be explained by the higher rate of unfavorable histologic features and a higher incidence of N+ or M+ disease in this patient cohort [11] . On the other hand, the rate of asymptomatic patients was highest (71.6%) among young patients in Denzinger et al's study [2] . However, there was no explanation for this discordance compared to other reports.
The rate of lymph node involvement was reported to be 3-24.5% in the previous studies [1, 2, 5, 7, 10, 11] . Lymph node involvement was 10.7% in our study which was considerably lower than that of Sanchez-Ortiz et al's study which was 24.5% [11] . About 30% of patients with RCC had evidence of metastatic disease at presentation [1] . In the young population the incidence of metastatic disease varied between 3-34% in various series [1, [5] [6] [7] 11, 12] . In our series, metastatic disease at presentation was 7.1%. Like lymph node metastasis, the highest incidence of metastatic tumor(34%) was found by the same group [11] . These authors suggested that younger patients had more advanced disease stages which might generally have an impact on the difference in tumor biology between younger and older patients [11] . Clear cell carcinoma is the most common histologic type of RCC in all age groups [4] . In the present study, clear cell and papillary histologic types were detected in 67.9% and 14.3% of the patients, respectively. Although very few studies reported that younger patients had a higher incidence of papillary histology than adults, clear cell type was the dominant subtype among all [3, 6] . In these studies, the incidence of papillary histology in younger and older patients were 13% versus 5% and 20.4% versus 11.4%, respectively [3, 6] . Abou El Fettouh et al. [1] and Denzinger et al. [2] also demonstrated a higher rate of papillary type (16% and 18.6%, respectively) in their series. Similar to ours, the former study did not include older patients. However, the latter study also presented a higher incidence of papillary RCC in older group compared to younger patients (19.4% versus 18.6%).
Sanchez-Ortiz et al. [11] detected lower incidence of Fuhrman Grade 1 and 2 tumors in this specific series(36.8 %). Yusim et al. [3] and Taccoen et al. [6] reported similar rates compared to our results 73%, 62.1% and 64.3%, respectively. Additionally, Fuhrman grade 4 was not detected in incidental tumors and tumors treated by NSS in the present study. However, there were no statistical differences in pathologic stage and Fuhrman grade except tumor size between incidental and symptomatic tumors. The symptomatic patients had greater sized tumors than the others in our study and this result was comparable with the previous studies [1, 12] .
RCC in young adults is usually organ confined at diagnosis and has a better prognosis than older adults [5, 6] . Besides, although young adults had more advanced stage and higher grade tumors, their survival was reported to be more favorable than older patients [11] . Despite these differences, one possible explanation for improved prognosis in younger patients might be due to the possibility of giving better response to aggressive therapy or potential biological differences in host-tumor interactions between younger and older patients with RCC [11] . Five year cancer specific survival rates differ between 67%-95.2% [1] [2] [3] 5, 6, 8, 10] . Although the followup period was short, the survival rate was similar to the literature in our study (cancer specific survival rate was 85.2% and mean survival was 30.6 months).
Young patients with RCC seem to have a higher incidence of symptomatic tumors, mostly with clear cell histology and with lower grades. Most common symptoms are pain and hematuria. Compared to symptomatic patients, incidentally discovered tumors have significantly smaller tumor size.
